Naloxone Talk Sheds Light On Switch Research Future
This article was originally published in The Tan Sheet
Executive Summary
FDA’s 2012 workshop on potential nonprescription use of naloxone for opioid overdoses underscored the potential usefulness of human factors research in the evolving landscape for switch. Largely considered a sub-category of self-selection studies, human factors research could gain importance as FDA moves into considering novel switches.
You may also be interested in...
OTC Switch Interest Cooled By Study Costs To Update Safety Data
Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.
OTC Switch Interest Cooled By Study Costs To Update Safety Data
Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.